AzTrials
AzTrials

Liver TransplantPhase 1/2LITTMUS-MGHNCT03577431

Liver Transplantation With Tregs at MGH

A Phase 1/2 study testing arTreg-CSB, leukapheresis and cyclophosphamide in people with Liver Transplant, run by National Institute of Allergy and Infectious Diseases (NIAID) at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a single-center, prospective, open-label, non-randomized clinical trial exploring cellular therapy to facilitate immunosuppression withdrawal in liver transplant recipients. Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Liver Transplant
What is being tested?
arTreg-CSB, leukapheresis and cyclophosphamide
Could I receive a placebo?
No, everyone receives an active treatment
How many people
9 participants
Where
1 siteUnited States
Study dates
29 Mar 2019to 5 Feb 2026
Phase
Phase 1/2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Eligibility:
  • Recipient:
  • Individuals must meet all of the following criteria to be eligible for this study:
  • Able to understand and provide informed consent
  • End-stage liver disease and listed for a living or deceased-donor primary solitary liver transplant
  • Agreement to use contraception
Show all 20Show fewer
  • Positive Epstein-Barr virus (EBV) antibody test and
  • In the absence of contraindication, vaccinations must be up to date per the DAIT Guidance for Patients in Transplant Trials (Refer to the Manual of Procedures)
  • Living Donor:
  • Living donors must meet all of the following criteria to be eligible for this study:
  • Able to understand and provide informed consent
  • Meets site-specific clinical donor eligibility requirements
  • Meets donor eligibility manufacturing requirements within 7 days prior to blood collection for manufacturing and
  • Willingness to donate appropriate biologic samples.
  • Deceased Donor:
  • Deceased donors must meet the following criteria for their recipients to be eligible for this study:
  • 1. Meets site-specific clinical donor eligibility requirements and 2. Meets donor eligibility manufacturing requirements.
  • Note:
  • There are several stages to this study.
  • Eligibility is evaluated at many time points during the study to assess whether a participant is safe to proceed to the next study stage.

Who cannot join

  • Recipient:
  • Individuals who meet any of the following criteria will not be eligible for this study:
  • History of previous organ, tissue or cell transplant requiring or potentially requiring immunosuppression
  • For cytomegalovirus (CMV) antibody negative recipients, a (CMV) antibody positive donor
  • Known contraindication to cyclophosphamide or Mesna administration
  • Serologic evidence of human immunodeficiency virus (HIV)-1/2 infection
Show all 26Show fewer
  • The need for chronic anti-coagulation that cannot be safely discontinued for a minimum of 1 week to safely perform a liver biopsy
  • End stage liver disease secondary to autoimmune etiology (autoimmune hepatitis, primary biliary cirrhosis, or primary sclerosing cholangitis) or other contraindications to drug withdrawal
  • Psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up visit schedule
  • Any form of substance abuse, psychiatric disorder, or other condition that, in the opinion of the investigator, may interfere with study compliance
  • Past or current medical problems, treatments or findings that are not listed above, which, in the opinion of the investigator, may:
  • -- pose additional risks from participation in the study,
  • interfere with the candidate's ability to comply with study requirements, or
  • impact the quality or interpretation of the data obtained from the study.
  • History of malignancy with a risk of recurrence judged by the investigator to be >1%, except for:
  • -- hepatocellular carcinoma,
  • -- completely treated in-situ cervical carcinoma, or
  • -- completely treated basal cell carcinoma.
  • Chronic use of systemic glucocorticoids or other immunosuppressives, or biologic immunomodulators.
  • Living Donor:
  • Living donors who meet the following criteria will not be eligible for this study:
  • <!-- -->
  • Any condition that, in the opinion of the investigator, may pose additional risks from participation in the study, may: -- interfere with the participant's ability to comply with study requirements or --impact the quality or interpretation of the data obtained from the study.
  • Deceased Donor:
  • Recipients of livers from deceased donors who meet the following criteria are ineligible for this study:
  • 1. Any condition that, in the opinion of the investigator, may pose additional risks or may impact the quality or interpretation of the data obtained from the study.

Trial locations and contacts

1 site in 1 country.

United States1 site

  • Massachusetts General Hospital: Transplantation

    Boston, Massachusetts, 02114

Other trials in United States

About this study

Official title: A Phase I/II Drug Withdrawal Study of Alloantigen-Specific Tregs in Liver Transplantation (ITN073ST)

This is a single-center, prospective, open-label, non-randomized clinical trial exploring cellular therapy to facilitate immunosuppression withdrawal in liver transplant recipients.

Read the detailed description

The researchers in this study plan to enroll 9 participants who will receive at least the target Treg product (arTreg-CSB) dose of 2.5 x 10^6 cells. Participants who receive at least 1 x 10^6 cells but < 2.5 x 10^6 cells as a result of low cell yield will be included in intent-to-treat (ITT) analysis.

Participants who successfully withdraw from all immunosuppression will undergo a research biopsy at 52 weeks following drug discontinuation to determine whether they meet the primary efficacy outcome of operational tolerance. Participants determined to be operationally tolerant will be followed until 104 weeks following drug discontinuation and have a research biopsy at that time to confirm that they remain operationally tolerant. Participants who fail drug withdrawal after 52 weeks but before 104 weeks will be followed until week 104 or 12 weeks after resuming immunosuppression, whichever is longer. The research biopsy at week 104 will be optional for these participants.

Participants who do not successfully withdraw from all immunosuppression will complete 104 weeks of High Intensity Safety Follow-up after failing immunosuppression withdrawal.

  • IMPORTANT NOTICE: * The National Institute of Allergy and Infectious Diseases and the Immune Tolerance Network do not recommend the discontinuation of immunosuppressive therapy for recipients of cell, organ, or tissue transplants outside of physician-directed, controlled clinical studies. Discontinuation of prescribed immunosuppressive therapy can result in serious health consequences and should only be performed in certain rare circumstances, upon the recommendation and with the guidance of your health care provider.
Being tested
arTreg-CSB, leukapheresis, cyclophosphamide, mesna, everolimus
Keywords
alloantigen-reactive Tregs ( arTreg), immunosuppression, operational tolerance

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • arTreg-CSBBiological

    Also called donor alloantigen specific regulatory T cells, CD4+CD25+CD127[lo] Treg cells

    Participants will receive a single dose of Treg product (arTreg-CSB). The target dose is 2.5 to 125 x 10^6 total cells. If a minimum arTreg-CSB dose of 1 to < 2.5 x 10^6 cells, the product will be infused. If the dose obtained after product manufacture is < 1 x 10^6 cells, the product will not be infused. When the dose obtained after product manufacture is > 125 x 10^6 cells, a dose aliquot will be prepared so that the administered dose will be ≤ 125 x 10^6 cells, and ≥ 2.5 to 125 x 10^6 total cells.

    Method of receipt: peripheral intravenous (IV) infusion, administered over 15 to 30 minutes.

  • leukapheresisProcedure or surgery

    Also called apheresis

    Leukapheresis will be the method employed to recover peripheral blood mononuclear cells (PBMCs) from the allograft recipient. The recipient will undergo the procedure prior to initiating the cyclophosphamide conditioning regimen.

    Procedure 72 to 120 hours prior to Treg product (arTreg-CSB) IV infusion.

  • cyclophosphamideDrug

    Also called Cytoxan®

    40 mg/kg administered intravenously (IV) within 24 to 72 hours prior to Treg product (arTreg-CSB) infusion.

  • mesnaDrug

    Also called Mesnex®

    Mesna is administered intravenously to inhibit hemorrhagic cystitis induced by cyclophosphamide. Administration of mesna is per institutional practice with cyclophosphamide.

  • everolimusDrug

    Also called EVR, Afinitor®, Zortress®

    EVR, an immunosuppressant (IS), is approved by the FDA for the prophylaxis of allograft rejection in adults receiving a liver transplant. Between day 30 and wk. 48 post-transplant, participant evaluation for eligibility to be converted to an EVR-based IS regimen will occur.

    At the start of conversion from tacrolimus (TAC) to EVR IS:EVR will be started at 1.5 mg taken by mouth BID, with dose adjusted to achieve a trough blood level of 5-8 ng/mL. Once an EVR trough level of ≥ 5 ng/mL is achieved, baseline TAC dose will be reduced to achieve a trough level of 3-5 ng/mL.

    When target EVR and TAC levels are achieved/ maintained over two consecutive measurements, and liver function tests, ALT and GGT, are ≤50 U/L, participants will be considered successfully converted to EVR-based IS regimen. EVR doses will be administered, monitored and adjusted over time, per protocol.

Study groups in NCT03577431
Study groupRoleWhat they receive
arTreg-CSBExperimentalarTreg CSB: alloantigen-reactive T regulatory cells costimulatory blockade per protocol. The investigational product is donor alloantigen-specific T regulatory cells (arTreg-CSB). Supportive regimen for receipt of arTregs-CSB includes everolimus, leukapheresis, cyclophosphamide, and mesna. Participants will receive a single dose of Treg product (arTreg-CSB). The target dose is 2.5 to 125 x 10^6 total cells. arTreg-CSB will be administered as a single peripheral intravenous (IV) infusion over approximately 15 to 30 minutes. Note: Participants who receive at least the minimum Treg product (arTreg-CSB) dose of 1 to < 2.5 x 10^6 cells will be included in intent-to-treat analysis.
Receives: Biological: arTreg-CSB; Procedure: leukapheresis; Drug: cyclophosphamide; Drug: mesna; Drug: everolimus

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Adverse Events (AEs) Attributed to the Investigational Product, arTreg-CSB

    The number of AEs attributed to the investigational product, arTreg-CSB.

    AEs will be attributed to arTreg-CSB when the AE is reported with possible or related attribution to arTreg-CSB.

    Measured: From arTreg-CSB infusion through completion of study participation (Up to 4.5 years)

  2. Severity of Adverse Events (AEs) Attributed to the Investigational Product, arTreg-CSB

    Assessment of the intensity of AEs attributed to the investigational product, arTreg-CSB.

    AEs will be attributed to arTreg-CSB when the AE is reported with possible or related attribution to arTreg-CSB.

    Grading according to the NCI Common Terminology Criteria for Adverse Events [NCI-CTCAE version 4.03].

    Measured: From arTreg-CSB infusion through completion of study participation (Up to 4.5 years)

  3. Number of Adverse Events (AEs) Attributed to the Investigational Product's Supportive Regimen (Leukapheresis, Cyclophosphamide and Mesna)

    The number of AEs attributed to the investigational product's supportive regimen (leukapheresis, cyclophosphamide, and mesna).

    AEs will be attributed to the supportive regimen when the AE is reported with possible or related attribution to leukapheresis, cyclophosphamide, or mesna.

    Measured: From ≤3 days prior to arTreg-CSB infusion through completion of study participation (Up to 4.5 years)

  4. Severity of Adverse Events (AEs) Attributed to the Investigational Product's Supportive Regimen (Leukapheresis, Cyclophosphamide and Mesna)

    Assessment of the intensity of AEs attributed to the investigational product's supportive regimen (e.g., leukapheresis, cyclophosphamide, and mesna).

    AEs will be attributed to the supportive regimen when the AE is reported with possible or related attribution to leukapheresis, cyclophosphamide, or mesna.

    Assessment of the intensity of AEs will be graded according to the NCI Common Terminology Criteria for Adverse Events [NCI-CTCAE version 4.03].

    Measured: From ≤3 days prior to arTreg-CSB infusion through completion of study participation (Up to 4.5 years)

  5. Number of Operationally Tolerant Participants

    Operational tolerance is defined as:

    • Discontinuation of immunosuppression for 52 weeks,
    • Alanine aminotransferase (ALT) ≤ 50 U/L, and
    • A liver biopsy at 52 weeks (±4 weeks) after the last dose of immunosuppression that meets the criteria noted per protocol.
    • Liver histology will be assessed by central pathology.

    Measured: 52 weeks (±4 weeks) after the last dose of immunosuppression

Secondary outcomes (18)

  1. Number of Adverse Events (AEs) Attributed to Leukapheresis

    Number of AEs with possible or related attribution to leukapheresis.

    Measured: From ≤3 days prior to arTreg-CSB infusion through completion of study participation (Up to 4.5 years)

  2. Severity of Adverse Events (AEs) Attributed to Leukapheresis

    Assessment of the intensity of AEs with possible or related attribution to leukapheresis.

    Assessment of the intensity of AEs will be graded according to the NCI Common Terminology Criteria for Adverse Events [NCI-CTCAE version 4.03].

    Measured: From ≤3 days prior to arTreg-CSB infusion through completion of study participation (Up to 4.5 years)

  3. Number of Adverse Events (AEs) Attributed to Cyclophosphamide

    Number of AEs with possible or related attribution to cyclophosphamide.

    Measured: From ≤3 days prior to arTreg-CSB infusion through completion of study participation (Up to 4.5 years)

  4. Severity of Adverse Events (AEs) Attributed to Cyclophosphamide

    Assessment of the intensity of AEs with possible or related attribution to cyclophosphamide.

    Assessment of the intensity of AEs will be graded according to the NCI Common Terminology Criteria for Adverse Events [NCI-CTCAE version 4.03].

    Measured: From ≤3 days prior to arTreg-CSB infusion through completion of study participation (Up to 4.5 years)

  5. Number of Adverse Events (AEs) Attributed to Mesna

    Number of AEs with possible or related attribution to mesna.

    Measured: From ≤3 days prior to arTreg-CSB infusion through completion of study participation (Up to 4.5 years)

  6. Severity of Adverse Events (AEs) Attributed to Mesna

    Assessment of the intensity of AEs with possible or related attribution to mesna.

    Assessment of the intensity of AEs will be graded according to the NCI Common Terminology Criteria for Adverse Events [NCI-CTCAE version 4.03].

    Measured: From ≤3 days prior to arTreg-CSB infusion through completion of study participation (Up to 4.5 years)

  7. Number of Participants Who Experience ≥Grade 3 Infections Following arTreg-CSB Infusion

    Number of participants that experience ≥grade 3 infectious AEs status post arTreg-CSB infusion.

    Assessment of the intensity of AEs will be graded according to the NCI Common Terminology Criteria for Adverse Events [NCI-CTCAE version 4.03].

    Measured: From arTreg-CSB infusion through completion of study participation (Up to 4.5 years)

  8. Number of Biopsy-Proven Acute or Chronic Rejections

    Number of participants with biopsy-proven AR or CR. The diagnosis of biopsy-proven acute and chronic allograft rejection will be diagnosed in accordance with Banff global assessment criteria.

    Measured: From arTreg-CSB infusion through completion of study participation (Up to 4.5 years)

  9. Severity of Biopsy-Proven Acute Rejections

    Assessment of the intensity of biopsy-proven AR at any time status post participant's receipt of arTreg-CSB infusion.

    Intensity of AR will be graded in accordance with the Banff global assessment criteria.

    Reference: Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997;25:658-63.

    Measured: From arTreg-CSB infusion through completion of study participation (Up to 4.5 years)

  10. Proportion of Participants with a Composite Outcome Measure of CR, Steroid Refractory AR, Retransplantation or Death Following Everolimus Conversion

    The proportion of participants who develop ≥1 of the following events following initiation of everolimus conversion: refractory Acute Rejection (AR), Chronic Rejection (CR), undergo retransplantation, or die during study participation.

    Everolimus is FDA approved for use in liver and kidney transplantation for prophylaxis of organ rejection.

    Measured: From ≥30 days post-transplant through completion of study participation (Up to 4.5 years)

  11. Number of AEs Attributed to Immunosuppression Withdrawal

    Number of AEs possibly or definitely related to immunosuppression withdrawal.

    Measured: From ≥30 days post-transplant through completion of study participation (Up to 4.5 years)

  12. Severity of AEs Attributed to Immunosuppression Withdrawal

    Assessment of the intensity of AEs possibly or definitely related to immunosuppression withdrawal.

    Assessment of the intensity of AEs will be graded according to the NCI Common Terminology Criteria for Adverse Events [NCI-CTCAE version 4.03].

    Measured: From ≥30 days post-transplant through completion of study participation (Up to 4.5 years)

  13. Number of Participants who Develop a Malignancy

    The number of participants that are diagnosed with malignancy, any type.

    Measured: Day of transplant through completion of study participation (Up to 4.5 years)

  14. Number of Participants who Develop de novo Donor Specific Antibodies (DSA)

    A de novo donor-specific alloantibody (DSA) is a newly developed alloantibody that targets the donor organ. Alloantibodies are important mediators of acute and chronic rejection.

    This measure is calculated as time from transplant until the earliest time of development of any de novo DSA.

    Measured: Baseline (pre liver transplant) through completion of study participation (Up to 4.5 years)

  15. Number of Participants who Develop de novo non-DSA HLA Antibodies

    The number of participants who, following liver transplant, develop anti-donor HLA alloantibodies defined by the presence of anti-HLA IgG antibodies.

    Measured: Baseline (pre liver transplant) through Completion of Study Participation (Up to 4.5 years)

  16. Proportion of Participants who, Though Clinically Stable for 52 Weeks after Discontinued Immunosuppression per Protocol Schedule, do not Fulfill the Study Definition of Tolerance

    Proportion of participants who have discontinued immunosuppression for 52 weeks, but have:

    • either an ALT greater than 50 U/L or
    • a liver biopsy at 52 weeks that does not show rejection but does not meet the biopsy criteria for operational tolerance (Reference: Demetris AJ, Bellamy C, Hubscher SG, et al. 2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. Am J Transplant 2016).

    Measured: Post-Transplant through Completion of Study Participation (Up to 4.5 years)

  17. Duration of Operational Tolerance

    Defined as the time from achievement of the primary endpoint to immunosuppression reinitiation or to the end of trial participation.

    Inclusion in this analysis is limited to those participants classified as operationally tolerant for the primary outcome measure.

    Measured: Post-transplant through Completion of Study Participation (Up to 4.5 years)

  18. Proportion of Participants who Successfully Discontinue Tacrolimus

    Proportion of participants who, per protocol:

    • fulfill eligibility for tacrolimus withdrawal,
    • subsequently achieve their last dose of tacrolimus,
    • remain tacrolimus-free for ≥12 weeks,
    • their liver function test, ALT is ≤50 U/L,
    • and their liver biopsy performed between 12 to 26 weeks status post the last dose of tacrolimus fulfills biopsy findings* for minimization of immunosuppression.
    • Biopsy findings: Liver histology will be assessed by central pathology. Biopsy findings for minimization of immunosuppression, per protocol. Reference: Demetris AJ, Bellamy C, Hubscher SG, et al. 2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. Am J Transplant 2016.

    Measured: Post-transplant through Completion of Study Participation (Up to 4.5 years)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Jul 2018
  2. Study start29 Mar 2019
  3. Primary completion5 Feb 2026
  4. Study completion5 Feb 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
9 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03577431
Sponsor's protocol ID
DAIT ITN073ST
Acronym
LITTMUS-MGH
Status last verified
Sep 2026
First submitted
22 Jun 2018
Last updated
16 Sep 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: The plan is to share data upon completion of the study in ImmPort, a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing arTreg-CSB, leukapheresis and cyclophosphamide in people with Liver Transplant, run by National Institute of Allergy and Infectious Diseases (NIAID) at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 20 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Adverse Events (AEs) Attributed to the Investigational Product, arTreg-CSB (time frame: From arTreg-CSB infusion through completion of study participation (Up to 4.5 years)). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03577431.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in